Shares of Celgene (CELG) were trading at an all-time high early Tuesday after a slew of analyst upgrades followed its investor presentation Monday. At the JPMorgan Healthcare Conference in San Francisco, the biotech issued financial guidance all the way out to 2017, when it predicted annual revenue will have more than doubled to $12 billion. It also said its psoriasis drug candidate Apremilast met the desired endpoints in its phase-three trials,